Program as of July 14, 2008

SUNDAY, JULY 20

CONCURRENT EDUCATIONAL SESSIONS
2:00 p.m.–4:00 p.m.

SESSION 1: TRANSLATIONAL CLINICAL TRIAL DESIGN
Chairperson: James L. Abbruzzese, UT M. D. Anderson Cancer Center, Houston, TX

Translational Clinical Trial Design
James L. Abbruzzese

Rational (and Irrational) Incorporation of Biomarkers into Early Clinical Trials
Mark J. Ratain, University of Chicago, Chicago, IL

Moving from Correlative Clinical Science to Predictive Medicine
Richard M. Simon, NIH-NCI-DCTD, Bethesda, MD

SESSION 2: COMPANION DIAGNOSTICS FOR PERSONALIZED MEDICINE
Chairperson: Laura J. van't Veer, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Gene Activity Provides Cancer Therapeutic Recommendations
Laura J. van’t Veer

Gene Signatures: Research Tools or Novel Diagnostics in Personalized Medicine?
Yixin Wang, Veridex, LLC, Warren, NJ

Integrating Genomics and Genetics into Clinical Trials for Patient Stratification
Charles M. Perou, University of North Carolina, Chapel Hill, NC

CONCURRENT EDUCATIONAL SESSIONS
4:00 p.m.–6:00 p.m.

SESSION 3: INCORPORATING DYNAMIC IMAGING INTO TRANSLATIONAL RESEARCH
Chairperson: Ronald G. Blasberg, Memorial Sloan-Kettering Cancer Center, New York, NY

Dynamic Reporter Gene Imaging in Translational Research
Ronald G. Blasberg

Dynamic Molecular Imaging of Signal Transduction Pathways in vivo
David Piwnica-Worms, Washington University School of Medicine, St. Louis, MO
Use of Dynamic Imaging as a Biomarker for Development of Anticancer Drugs
Jeffrey L. Evelhoch, Amgen, Inc., Thousand Oaks, CA

SESSION 4: THE USE OF SNPS TO PERSONALIZE CANCER THERAPIES
Chairperson: James M. Ford, Stanford University School of Medicine, Stanford, CA

SNPs as Prognostic Indicators in Cancer Outcomes
Kim M. Hirshfield, The Cancer Institute of New Jersey, New Brunswick, NJ

SNPs as Predictive Markers for Cancer Treatment
James M. Ford

New Approaches to Multidrug Resistance in Cancer
Michael M. Gottesman, National Cancer Institute, Bethesda, MD

KEYNOTE ADDRESS
6:30 p.m.–7:30 p.m.

Introduction
William N. Hait, OrthoBiotech Oncology Research and Development, a unit of Johnson and Johnson Research and Development, L.L.C., Raritan, NJ

Overcoming Resistance to Molecularly Targeted Cancer Therapy
Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY

RECEPTION
7:30 p.m.–9:00 p.m.

MONDAY, JULY 21

PLENARY SESSION 1: DEVELOPMENT OF RATIONAL COMBINATION THERAPIES
Chairpersons: Chris H. Takimoto, OrthoBiotech Oncology Research and Development, Radnor, PA and José Baselga, Vall d’Hebron University Hospital, Barcelona, Spain
8:00 a.m.-10:30 a.m.

Introduction
Chris H. Takimoto

Combinatorial Approaches with Signal Transduction Inhibitors
José Baselga

Designing Rational Combinations of Targeted Therapies: Factual Foresight or Flights of Fancy?
Chris H. Takimoto

Modulation of Anticancer Agents in the Clinic: Challenges and Opportunities
Miguel A. Villalona-Calero, The Ohio State University Medical Center, Columbus, OH

Concluding Remarks
José Baselga

PLENARY SESSION 2: BIOLOGIC INSIGHTS FROM TARGETING THE HER PATHWAY
Chairperson: Gwendolyn A. Fyfe, Genentech, Inc., South San Francisco, CA
11:00 a.m.–1:00 p.m.
Introductory Remarks
José Baselga, Vall d'Hebron University Hospital, Barcelona, Spain

What Have We Learned From Preclinical and Clinical Studies of EGFR Tyrosine Kinase Inhibitors in Lung Cancer?
William Pao, Memorial Sloan-Kettering Cancer Center, New York, NY

Challenges in Interpreting Clinical Results with HER Kinase Inhibitors
Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY

Target-Driven Drug Development: Lessons from HER2
Robert L. Cohen, Genentech, Inc., South San Francisco, CA

MENTORING LUNCH FOR EARLY-CAREER INVESTIGATORS
1:00 p.m.–2:00 p.m.

FORUM 1: WHAT ARE THE MAJOR BARRIERS TO TRANSLATIONAL RESEARCH AND THEIR POTENTIAL SOLUTIONS?
Chairperson: William G. Nelson, V, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
2:00 p.m.-3:00 p.m.

Going with the Flow: A Framework for Translational Research
Ernest T. Hawk, UT M. D. Anderson Cancer Center, Houston, TX

The Emerging Translational Oncology Tool Kit
Stephen H. Friend, Merck & Co., Inc., North Wales, PA

New Epigenetic Drug Targets
William G. Nelson, V

FORUM 2: REGULATORY BASIS FOR PERSONALIZED MEDICINE
Chairperson: Steven I. Gutman, Food and Drug Administration, Rockville, MD
3:00 p.m.-4:00 p.m.

FDA Regulation of Biomarkers: Turning the Critical Path into a Yellow Brick Road
Steven I. Gutman

Legal and Regulatory Issues Affecting Clinical Use of Personalized Medicine
Barbara Evans, University of Houston, Houston, TX

Statistics for Diagnostics: What Makes a Diagnostic Test Informative
R. Lakshmi Vishnuvajjala, Food and Drug Administration, Rockville, MD

CONCURRENT SESSIONS
4:00 p.m.–6:00 p.m.

SESSION 1: CAREERS IN CLINICAL AND TRANSLATIONAL CANCER RESEARCH
(short talks and panel discussion)
Chairperson to be announced

The Changing Role of Industry in Oncology Clinical/Translational Research: Collaboration, Collaboration, Collaboration
Gwendolyn A. Fyfe, Genentech, Inc., South San Francisco, CA

A Career in Translational Cancer Medicine
James H. Doroshow, National Cancer Institute - DCTD, Bethesda, MD
SESSION 2: HOW TRANSLATIONAL RESEARCH IS TRANSFORMING MYELOMA
Chairperson: Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA

PK/PD Relationships: Following the Target of Bortezomib (VELCADE)
Julian Adams, Infinity Pharmaceuticals, Inc., Cambridge, MA

Oncogenomics to Target Myeloma Cells in the Bone Marrow Microenvironment
Kenneth C. Anderson

Preclinical Rationale Leading to Clinical Benefit: Multiple Myeloma as a Poster Child
Sagar Lonial, Emory University Winship Cancer Institute, Atlanta, GA

SESSION 3: MULTITARGETED VS. OLIGOTARGETED KINASE INHIBITORS - PREDICTING LIKELIHOOD OF SUCCESS
Chairperson: John E.L. Wong, National University of Singapore, Singapore

Monitoring and Optimizing Biologic Effects of TKIs in the Clinic: When the One Drug-One Target Model No Longer Applies
Kimberly L. Blackwell, Duke University Medical Center, Durham, NC

Designed Multispecific Kinase Inhibitors
Kevan Shokat, University of California, San Francisco, CA

Targeting Raf Kinase: Advantages of Selectivity for the BRAFV600E Oncoprotein
Gideon Bollag, Plexxikon, Inc., Berkeley, CA

POSTER SESSION A
6:00 p.m.–8:00 p.m.

TUESDAY, JULY 22

PLENARY SESSION 3: HOW TO SHORTEN THE TIME IT TAKES TO GET A DRUG INTO THE CLINIC
Chairpersons: Nicholas C. Dracopoli, Johnson & Johnson, Radnor, PA and James H. Doroshow, National Cancer Institute - DCTD, Bethesda, MD
8:00 a.m.–10:30 a.m.

Introduction
James H. Doroshow

Biomarkers: Help or Hindrance in Clinical Development?
Nicholas C. Dracopoli

Barriers to Clinical Trial Activation: Improving the Process
Alan B. Sandler, Vanderbilt University, Nashville, TN

Title to be announced
James H. Doroshow

Panel Discussion
PLENARY SESSION 4: PREDICTING AND PREVENTING DRUG RESISTANCE
Chairpersons: William S. Dalton, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL and Branimir I. Sikic, Stanford University Medical Center, Stanford, CA
10:45 a.m.-1:15 p.m.

Introduction
Branimir I. Sikic

Drug Resistance and ABC Transporters: Old Paradigms Invigorated by New Data
Susan E. Bates, National Cancer Institute, Bethesda, MD

Lessons from Translational Trials Targeting MDR1/P-glycoprotein
Branimir I. Sikic

The Influence of the Tumor Microenvironment on Drug Response and Drug Resistance
William S. Dalton

Concluding Remarks
William S. Dalton

MENTORING LUNCH FOR EARLY-CAREER INVESTIGATORS
1:15 p.m.-2:30 p.m.

PLENARY SESSION 5: TARGETING THE PI3K/AKT/PTEN PATHWAY
Chairpersons: Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown, MA and Peter J. Houghton, St. Jude Children's Research Hospital, Memphis, TN
2:30 p.m.–5:00 p.m.

Introduction
Jeffrey A. Engelman

PTEN Hamartomatous Tumor Syndromes (PHTS)- Rare Syndromes with Great Relevance to Common Cancers and Targeted Drug Development
Phillip A. Dennis, National Cancer Institute - CCR, Bethesda, MD

Targeting the PI3K Pathway to Overcome Resistance to Tyrosine Kinase Inhibitors
Jeffrey A. Engelman

Targeting the IGF-1/mTOR Pathway
Peter J. Houghton

Concluding Remarks
Peter J. Houghton

POSTER SESSION B
5:00 p.m.–7:00 p.m.

WEDNESDAY, JULY 23

PLENARY SESSION 6: TUMOR MICROENVIRONMENT
Chairperson: Lisa M. Coussens, UCSF Comprehensive Cancer Center & Cancer Research Institute, San Francisco, CA
8:00 a.m.–10:30 a.m.

Introduction
Lisa M. Coussens
Polarized Immune Responses Regulate Epithelial Cancer Development  
Lisa M. Coussens  
TGF-beta Regulation of the Tumor Microenvironment  
Harold L. Moses, Vanderbilt-Ingram Cancer Center, Nashville, TN  

Therapeutic Targeting of Angiogenesis and the Tumor Microenvironment in Mouse Models of Cancer  
Douglas Hanahan, UCSF Comprehensive Cancer Center & Cancer Research Institute, San Francisco, CA  

Concluding Remarks  
Lisa M. Coussens  

PLENARY SESSION 7: ORGAN-BASED RESEARCH  
Chairpersons: Joyce M. Slingerland, University of Miami Miller School of Medicine, Miami, FL and George D. Demetri, Dana-Farber Cancer Institute, Boston, MA  
11:00 a.m.–1:30 p.m.  

Introduction  
Joyce M. Slingerland  

Molecular Rationale and Preclinical Data to Support Combined Src and Aromatase Inhibitor Therapy for ER-Positive Breast Cancer  
Joyce M. Slingerland  

Title to be announced  
George D. Demetri  

Treating Advanced Prostate Cancer by Disrupting Host Cell Interactions in the Tumor Microenvironment  
Kenneth J. Pienta, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI  

CLOSING REMARKS  
1:30 p.m.–1:45 p.m.  
Nicholas C. Dracopoli, Centocor Research and Development, Inc., Radnor, PA  

DEPARTURE